South Africa has launched a landmark HIV vaccine trial, enrolling the first 20 participants in what is the first African-led clinical study of its kind.
The trial, named BRILLIANT 011, is being conducted at the Desmond Tutu HIV Foundation in Cape Town and involves partnerships with the South African Medical Research Council (SAMRC) and Wits Health Consortium. The initiative includes scientists from several African countries and is predominantly led by African women researchers.
The vaccine aims to stimulate the immune system to produce antibodies that can neutralize HIV. If early results show a strong immune response, the study will expand to larger trials. Researchers also hope the approach could eventually contribute to improved treatments for those already living with HIV.
South Africa has one of the highest HIV burdens in the world, with recent estimates indicating over 8 million people living with the virus. While antiretroviral treatment is widely available, prevention remains a challenge.
This trial represents a significant step in locally driven research to develop effective, long-term prevention tools.
